Dynamic heterogeneity of proteomic expression in human cancer cells does not affect Cdk1/Cdk4 co-expression

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 3, 2008, Pages 237-254

  Warenius, Hilmar ^a,b   Howarth, Amanda ^b   Seabra, Laurence ^c   Kyritsi, Leto ^d   Dormer, Roisin ^d   Anandappa, Shanez ^e   Thomas, Carole ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Theryte Ltd   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e University of Liverpool Cancer Research Centre ^*

Author keywords

Cancer; CDDP; Cdk1; Cdk4; Cell lines; Cyclin D1; Heterogeneity; Human; In vitro; Tumour

Indexed keywords

ACTIN; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4;

ARTICLE; CELL DEATH; CELL DIVISION; CELL HETEROGENEITY; DRUG ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 56749103180     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Betensky, R., Louis, D., Cairncross, J. (2002). Influence of unrecognised molecular heterogeneity on randomised clinical trials. J Clin Oncol., 10, 2495-2499.
2. Chen, E., Siu, L. (2005). Development of molecular targeted anticancer agents: successes, failures and future directions. Curr Parmaceutical Design, 11, 265-272.
3. Codegoni, A., Nicoletti, M., Buraggi, G., Valoti, G., Giavazzi, R., D'Incalci, M., Landoni, F., Maneo, A., Broggini M. (1998). Molecular characterisation of a panel of human ovarian carcinoma xenografts. Eur J Cancer, 34, 1432-1438.
4. Fidler, I., Hart, I. (1982). Biological diversity in metastatic neoplasms: origins and implications. Science, 217, 998-1003.
5. Götte, K., Schäfer, C., Riedel, F., Arens, N., Hörnmann, K. (2004). Intratumoral genomic heterogeneity in primary head and neck cancer and corresponding metastases detected by dual-FTSH. Oncol Rep., 11, 17-23.
6. Grassl, J., Morishita, M., Lewis, P., Leonard, R., Thomas, G. (2006). Profiling the breast cancer proteome - the new tool of the future. Clin Oncol., 18, 581-586.
7. Harada, K., Nishizaki, T., Ozaki, S., Kubota, H., Ito, H., Sasaki, K. (1998). Intratumoural cytogenetic heterogeneity detected by comparative genomic hybridisation and laserscanning cytometry in human gliomas. Cancer Res., 58, 5694-5700.
8. Khalique, L., Ayhan, A., Weale, M., Jacobs, I., Ramus, S., Gayther, S. (2007). Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol., 211, 286-295.
9. Li, J., Xu, B., Shakhtour, B., Deane, N., Merchant, N., Heslin, M., Washington, K., Coffey, R., Beauchamp, R., Shyr, Y., Billheimer, D. (2007). Variability of in situ proteomic profiling and implications for study design in colorectal tumors. Int J Oncol., 31, 103-111.
10. Losi, L., Baisse, B., Bouzourene, H., Benhattar, J. (2005). Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis, 26, 916-922.
11. Ma, Y., Ding, Z., Qian, Y., Shi, X., Castranova, V., Harner, J., Guo, L. (2006). Predicting cancer drug response by proteomic profiling. Clin Cancer Res., 12, 4583-4589.
12. Moch, H., Schraml, P., Budendorf, L., Mirlacher, M., Kononen, J., Gasser, T., Mihatsch, M., Kallioniemi, O., Sauter, G. (1999). High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal carcinoma. Am. J. Pathol., 154, 981-986.
13. Nishizuka, S., Charbonneau, L., Young, L., Major, S., Reinhold, W., Waltham, M., Kouros-Mehr, H., Bussey, K., Lee, J., Espina, V., Munson, P., Petricoin III, E., Liotta, L., Weinstein, J. (2003). Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. PNAS, 100, 14229-14234.
14. O'Sullivan, M., Budhraja, V., Sadovsky, Y., Pfeifer, J. (2005). Tumour Heterogeneity affects the precision of microarray analysis. Diagn Mol Pathol, 14, 65-71.
15. Owens, A. Jr. (1982). Tumor Cell Heterogeneity: A Perspective. In Owens, A. Jr, Coffey, D., Baylin, S., Editors. Tumor Cell Heterogeneity. Origins and Implications. Bristol-Myers Cancer Symposia Vol. 4. New York, London, Toronto, Sydney San Francisco; Academic Press, pages 3-6.
16. Reis-Filho, J., Westbury, C., Pierga, J-Y. (2006). The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol., 59, 225-231.
17. Roshke, A., Tonon, G., Gelhaus, K., McTyre, N., Bussey, K., Lababidi, S., Scudiero, D., Weinstein, J., Kirsch, I. (2003). Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res, 63, 8634-8647.
18. Seabra, L., Warenius, H. (2007). Proteomic co-expression of cyclin-dependent kinases 1 and 4 in human cancer cells. Eur J Cancer, 43, 1483-1492.
19. Tonin, P., Hudson, T., Rodier, F., Rodier, F., Bossolasco, M., Lee, P., Novak, J., Mandersom, E., Provencher, D., Mes-Masson A-M. (2001). Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene, 20, 6617-6626.
20. Von Hoff, D. (1998). There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hilda Rosenthal Foundation Award Lecture. Clin Cancer Res, 4, 1079-1086.
21. Warenius, H. (2002). Are critical normal gene products in cancer cells the real therapeutic targets? Anticancer Res, 22, 2651-2656.
22. Warenius, H., Browning, P., Britten, R., Peacock, J., Rapp, U. (1994). C-raf-1 proto-oncogene expression relates to radiosensitivity rather than radioresistance. Eur J Cancer, 30A, 369-375.
23. Warenius, H., Jones, M., Gorman, T., McLeish, R., Seabra, L., Barraclough, R., Rudland, P. (2000). Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Brit J Cancer, 83, 1084-1095.
24. Warenius, H., Seabra, L., Kyritsi, L., White, R., Dormer, R., Anandappa, S., Thomas, C., Howarth, A. (2008). Theranostic proteomic profiling of cyclins, cyclin dependent kinases and ras in human cancer cell lines is dependent on p53 mutational status. Int J Oncology. 32, 895-907.
25. Warenius, H., Seabra, L., Maw, P. (1996). Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int J Cancer. 67, 224-231.
26. Yang, G., Ross, D., Kuang, W., Brown, P., Weigel, R. (1999). Combined SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res. 27, 1517-523.